$DNLI
Denali Therapeutics Inc. Stock $dnli

$dnli Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000171489920000118 Filed on November 05, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q4
Revenue	$316.8M	$9.393M	$4.672M
YoY Change	6680.82%	-30.95%	-96.28%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$18.00M	$15.80M	$10.90M
YoY Change	65.14%	41.07%	-0.91%
% of Gross Profit
Research & Development	$54.70M	$53.70M	$51.60M
YoY Change	6.01%	2.21%	29.32%
% of Gross Profit
Depreciation & Amortization	$2.100M	$2.100M	$2.100M
YoY Change	0.0%	10.53%	-12.5%
% of Gross Profit
Operating Expenses	$72.70M	$69.51M	$62.40M
YoY Change	16.51%	9.02%	22.35%
Operating Profit		-$60.12M	-$57.76M
YoY Change		19.86%	-177.3%
Interest Expense	$1.600M	$1.900M	$3.800M
YoY Change	-57.89%	-50.0%	35.71%
% of Operating Profit
Other Income/Expense, Net		$1.944M
YoY Change		-48.6%
Pretax Income	$245.7M	-$58.20M	-$54.00M
YoY Change	-555.0%	25.43%	-169.68%
Income Tax	$800.0K	$56.00K	$100.0K
% Of Pretax Income	0.33%
Net Earnings	$244.9M	-$58.23M	-$54.03M
YoY Change	-553.31%	25.87%	-169.68%
Net Earnings / Revenue	77.3%	-619.91%	-1156.36%
Basic Earnings Per Share		-$0.54
Diluted Earnings Per Share	$1.811M	-$0.54	-$561.9K
COMMON SHARES
Basic Shares Outstanding	119.9M shares	107.5M shares	96.03M shares
Diluted Shares Outstanding		107.5M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.470B	$961.2M	$415.4M
YoY Change	253.8%	100.5%	-10.53%
Cash & Equivalents	$507.1M	$351.0M	$79.45M
Short-Term Investments	$962.6M	$610.2M	$335.9M
Other Short-Term Assets	$20.30M	$9.700M	$14.70M
YoY Change	38.1%	-35.33%	-10.91%
Inventory
Prepaid Expenses
Receivables	$8.593M
Other Receivables
Total Short-Term Assets	$1.496B	$970.9M	$430.0M
YoY Change	247.8%	96.38%	-10.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$40.85M	$42.27M	$46.73M
YoY Change	-12.6%	-10.99%	85.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$32.70M	$20.30M	$39.90M
YoY Change	-18.05%	-13.62%	-73.02%
Other Assets	$2.462M	$3.858M	$2.659M
YoY Change	-7.41%	19.0%	-67.19%
Total Long-Term Assets	$108.6M	$99.44M	$123.2M
YoY Change	-11.83%	-8.44%	-31.99%
TOTAL ASSETS
Total Short-Term Assets	$1.496B	$970.9M	$430.0M
Total Long-Term Assets	$108.6M	$99.44M	$123.2M
Total Assets	$1.604B	$1.070B	$553.2M
YoY Change	189.98%	77.5%	-16.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.071M	$2.806M	$2.590M
YoY Change	-58.65%	38.77%	36.96%
Accrued Expenses	$8.315M	$11.53M	$6.569M
YoY Change	26.58%	-25.45%	-22.9%
Deferred Revenue	$19.91M	$28.02M	$18.74M
YoY Change	6.27%	54.06%	63.99%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$71.70M	$105.4M	$45.34M
YoY Change	58.12%	125.8%	38.3%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$701.0K	$379.0K	$379.0K
YoY Change	84.96%	-1.81%	-19.53%
Total Long-Term Liabilities	$701.0K	$379.0K	$379.0K
YoY Change	84.96%	-1.81%	-19.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$71.70M	$105.4M	$45.34M
Total Long-Term Liabilities	$701.0K	$379.0K	$379.0K
Total Liabilities	$453.7M	$187.8M	$158.3M
YoY Change	186.56%	13.94%	37.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$354.4M	-$599.3M	-$425.6M
YoY Change	-16.72%	61.31%	86.7%
Common Stock	$1.531M	$1.524M	$1.288M
YoY Change	18.87%	18.51%	1.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.151B	$882.6M	$394.9M
YoY Change
Total Liabilities & Shareholders Equity	$1.604B	$1.070B	$553.2M
YoY Change	189.98%	77.5%	-16.43%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q4
OPERATING ACTIVITIES
Net Income	$244.9M	-$58.23M	-$54.03M
YoY Change	-553.31%	25.87%	-169.68%
Depreciation, Depletion And Amortization	$2.100M	$2.100M	$2.100M
YoY Change	0.0%	10.53%	-12.5%
Cash From Operating Activities	$514.0M	$0.00	-$47.70M
YoY Change	-1177.57%	-100.0%	-151.18%
INVESTING ACTIVITIES
Capital Expenditures	-$1.200M	-$700.0K	-$2.800M
YoY Change	-57.14%	-75.0%	100.0%
Acquisitions
YoY Change
Other Investing Activities	-$366.1M	-$211.4M	$45.10M
YoY Change	-911.75%	-503.44%	-175.29%
Cash From Investing Activities	-$367.3M	-$212.2M	$42.40M
YoY Change	-966.27%	-528.69%	-169.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	9.500M	425.9M	2.000M
YoY Change	375.0%	60742.86%	17.65%
NET CHANGE
Cash From Operating Activities	514.0M	0.000	-47.70M
Cash From Investing Activities	-367.3M	-212.2M	42.40M
Cash From Financing Activities	9.500M	425.9M	2.000M
Net Change In Cash	156.2M	213.7M	-3.300M
YoY Change	-4833.33%	979.29%	-109.85%
FREE CASH FLOW
Cash From Operating Activities	$514.0M	$0.00	-$47.70M
Capital Expenditures	-$1.200M	-$700.0K	-$2.800M
Free Cash Flow	$515.2M	$700.0K	-$44.90M
YoY Change	-1247.44%	-102.54%	-147.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001714899
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38311
	dei	Entity Registrant Name EntityRegistrantName	Denali Therapeutics Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3872213
	dei	Entity Address Address Line1 EntityAddressAddressLine1	161 Oyster Point Blvd
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	866-8548
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	DNLI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	119918496	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	351047000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79449000	USD
CY2020Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	610154000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	335907000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9665000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14675000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	970866000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	430031000	USD
CY2020Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	20341000	USD
CY2019Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	39886000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42265000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46732000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32976000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33923000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3858000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2659000	USD
CY2020Q3	us-gaap	Assets Assets	1070306000	USD
CY2019Q4	us-gaap	Assets Assets	553231000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2806000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2590000	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9010000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8739000	USD
CY2020Q3	dnli	Accrued Clinical Costs Current AccruedClinicalCostsCurrent	4689000	USD
CY2019Q4	dnli	Accrued Clinical Costs Current AccruedClinicalCostsCurrent	5042000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11531000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6569000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4508000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3665000	USD
CY2020Q3	dnli	Contract With Customer Liability From Related Parties Current ContractWithCustomerLiabilityFromRelatedPartiesCurrent	44854000	USD
CY2019Q4	dnli	Contract With Customer Liability From Related Parties Current ContractWithCustomerLiabilityFromRelatedPartiesCurrent	0	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	28015000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	18739000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	105413000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	45344000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	16557000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	43753000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	65407000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	68865000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	379000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	379000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	187756000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	158341000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	119795216	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	119795216	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96189935	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96189935	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	1524000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1288000	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1480315000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	818803000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	11000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	350000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-599300000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-425551000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	882550000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	394890000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1070306000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	553231000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9388000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13508000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18751000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21717000	USD
CY2020Q3	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	5000	USD
CY2019Q3	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	96000	USD
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	93000	USD
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	289000	USD
CY2020Q3	us-gaap	Revenues Revenues	9393000	USD
CY2019Q3	us-gaap	Revenues Revenues	13604000	USD
	us-gaap	Revenues Revenues	18844000	USD
	us-gaap	Revenues Revenues	22006000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	53704000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52544000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	157872000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	141831000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15805000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11215000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42332000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35601000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	69509000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	63759000	USD
	us-gaap	Operating Expenses OperatingExpenses	200204000	USD
	us-gaap	Operating Expenses OperatingExpenses	177432000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-60116000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-50155000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-181360000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-155426000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1944000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3782000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7611000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11411000	USD
CY2020Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-58172000	USD
CY2019Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-46373000	USD
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-173749000	USD
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-144015000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	56000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-113000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-426000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-58228000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-46260000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-173749000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-143589000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-540000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-317000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-339000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	1211000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58768000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46577000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-174088000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-142378000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.48
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.65
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.50
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	107490702	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	95859048	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	105217770	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	95449570	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	394890000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	193948000	USD
	dnli	Stock Issued During Period Value Stock Purchase Agreement StockIssuedDuringPeriodValueStockPurchaseAgreement	420146000	USD
	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	11133000	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36521000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-173749000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-339000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	882550000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	502167000	USD
CY2020Q3	dnli	Stock Issued During Period Value Stock Purchase Agreement StockIssuedDuringPeriodValueStockPurchaseAgreement	420146000	USD
CY2020Q3	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	5753000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13252000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-58228000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-540000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	882550000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	546845000	USD
	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	4156000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	85000	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	29489000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-143589000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1211000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	438197000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	475173000	USD
CY2019Q3	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	679000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	21000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8901000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-46260000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-317000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	438197000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-173749000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-143589000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6410000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5936000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	36521000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	29489000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1074000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	4032000	USD
	dnli	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	1669000	USD
	dnli	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	-2333000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-18000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	427000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3819000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5812000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	147000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	466000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4880000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2876000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-17920000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2797000	USD
	dnli	Increase Decrease In Contract With Customer Liability Related Parties IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties	44854000	USD
	dnli	Increase Decrease In Contract With Customer Liability Related Parties IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-97763000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-103933000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	687523000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	219139000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1900000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15146000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	433557000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	339612000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-255866000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	105327000	USD
	dnli	Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement	420146000	USD
	dnli	Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	193948000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	11133000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4156000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	625227000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4156000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	271598000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	5550000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80949000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78623000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	352547000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84173000	USD
	dnli	Noncash Tenant Improvements Paid By Landlord NoncashTenantImprovementsPaidByLandlord	0	USD
	dnli	Noncash Tenant Improvements Paid By Landlord NoncashTenantImprovementsPaidByLandlord	11343000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	32000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1500000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the Condensed Consolidated Balance Sheets and Statements of Operations and Comprehensive Loss.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and forward foreign currency exchange contracts. Substantially all of the Company’s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Condensed Consolidated Balance Sheets. As of September 30, 2020 and December 31, 2019, the Company has no off balance sheet concentrations of credit risk. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to counterparty credit risk on all of its derivative financial instruments. The Company has established and maintains strict counterparty credit guidelines and enters into hedges only with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company does not require collateral to be pledged under these agreements.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.</span></div>The COVID-19 pandemic has caused increased risk and uncertainty for the Company. Credit risk associated with investments in securities may increase if any institution with which the Company has an investment is significantly impacted by the COVID-19 pandemic. As of September 30, 2020, the Company has not realized any losses on its cash deposits or investments. Further, COVID-19 may impact the timelines and progress of the Company's preclinical activities and clinical trials, and may impact its ability to raise capital in the near term.
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2020Q3	us-gaap	Derivative Assets DerivativeAssets	109000	USD
CY2020Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	957244000	USD
CY2020Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	173000	USD
CY2020Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	173000	USD
CY2019Q4	us-gaap	Derivative Assets DerivativeAssets	85000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	446030000	USD
CY2019Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	8000	USD
CY2019Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	8000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	351047000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79449000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82673000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77123000	USD
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	USD
CY2019Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	352547000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80949000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84173000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78623000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	630133000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	377000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	15000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	630495000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	375094000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	729000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	30000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	375793000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2019	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-100000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-100000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-400000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-400000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P2Y
CY2018Q4	dnli	Number Of Indications NumberOfIndications	3	indication
CY2018Q4	dnli	Number Of Indications NumberOfIndications	3	indication
CY2020Q3	us-gaap	Revenues Revenues	9393000	USD
CY2019Q3	us-gaap	Revenues Revenues	13604000	USD
	us-gaap	Revenues Revenues	18844000	USD
	us-gaap	Revenues Revenues	22006000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.090
CY2020Q3	us-gaap	Lease Cost LeaseCost	2800000	USD
	us-gaap	Lease Cost LeaseCost	8300000	USD
CY2019Q3	us-gaap	Lease Cost LeaseCost	2600000	USD
	us-gaap	Lease Cost LeaseCost	7400000	USD
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y7M6D
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
	us-gaap	Operating Lease Payments OperatingLeasePayments	7200000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	3400000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2536000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	10391000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10731000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	11083000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	11447000	USD
CY2020Q3	dnli	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	54074000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	100262000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	30347000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	69915000	USD
CY2020Q3	us-gaap	Sublease Income SubleaseIncome	900000	USD
	us-gaap	Sublease Income SubleaseIncome	2800000	USD
CY2019Q3	us-gaap	Sublease Income SubleaseIncome	900000	USD
	us-gaap	Sublease Income SubleaseIncome	1700000	USD
CY2020Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	715000	USD
CY2020Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	2925000	USD
CY2020Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	3009000	USD
CY2020Q3	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	3096000	USD
CY2020Q3	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	876000	USD
CY2020Q3	dnli	Lessor Operating Lease Payment To Be Received After Year Four LessorOperatingLeasePaymentToBeReceivedAfterYearFour	0	USD
CY2020Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	10621000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11640734	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.96
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3371048	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	25.00
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	874357	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.63
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	617360	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	20.60
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13520065	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.77
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	11775333	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	18.00
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5437269	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	13.80
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13252000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8901000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	36521000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29489000	USD
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15950786	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15950786	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12818053	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12818053	shares

Files In Submission

Name	View Source	Status
0001714899-20-000118-index-headers.html	Edgar Link	pending
0001714899-20-000118-index.html	Edgar Link	pending
0001714899-20-000118.txt	Edgar Link	pending
0001714899-20-000118-xbrl.zip	Edgar Link	pending
dnli-20200930.htm	Edgar Link	pending
dnli-20200930.xsd	Edgar Link	pending
dnli-20200930_cal.xml	Edgar Link	unprocessable
dnli-20200930_def.xml	Edgar Link	unprocessable
dnli-20200930_htm.xml	Edgar Link	completed
dnli-20200930_lab.xml	Edgar Link	unprocessable
dnli-20200930_pre.xml	Edgar Link	unprocessable
exhibit101q32020.htm	Edgar Link	pending
exhibit102q32020.htm	Edgar Link	pending
exhibit103q32020.htm	Edgar Link	pending
exhibit104q32020.htm	Edgar Link	pending
exhibit105q32020.htm	Edgar Link	pending
exhibit106q32020.htm	Edgar Link	pending
exhibit311q32020.htm	Edgar Link	pending
exhibit312q32020.htm	Edgar Link	pending
exhibit321q32020.htm	Edgar Link	pending
exhibit322q32020.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_01a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DNLI
Denali Therapeutics Inc. Stock $dnli

2020 Q4 Form 10-Q Financial Statement

#000171489920000118 Filed on November 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNLI Denali Therapeutics Inc. Stock $dnli

2020 Q4 Form 10-Q Financial Statement

#000171489920000118 Filed on November 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNLI
Denali Therapeutics Inc. Stock $dnli